

Smokers and Vapers May Be at Greater Risk for Covid-19

 [nytimes.com/2020/04/09/health/coronavirus-smoking-vaping-risks.html](https://www.nytimes.com/2020/04/09/health/coronavirus-smoking-vaping-risks.html)

Jan
Hoffman

April 9,
2020



Anxious times — like a pandemic — can lead to unhealthy but self-soothing habits, whether it's reaching for a bag of potato chips, more chocolate or another glass of wine. But some stress-reducing behaviors are alarming to medical experts right now — namely vaping and smoking of tobacco or marijuana.

Because the coronavirus attacks the lungs, this is exactly the moment, they say, when people should be tapering — or better yet, stopping — their use of such products, not escalating them.

"Quitting during this pandemic could not only save your life, but by preventing the need for your treatment in a hospital, you might also save someone else's life," said Dr. Jonathan Winickoff, director of pediatric research at the Tobacco Research and Treatment Center at Massachusetts General Hospital.

[How to Quit Smoking and Vaping During the Coronavirus Pandemic](#)

[People who smoke and vape may be at greater risk for Covid-19, but quitting is hard, especially now. The good news: There are a lot of helpful resources.](#)

[April 9, 2020](#)

On Thursday, Dr. Winickoff joined the Massachusetts attorney general, Maura Healey, to issue an advisory alerting the public and particularly young people that smoking and vaping can also exacerbate the risks of spreading Covid-19.

“You bring this device or cigarette to your mouth to inhale and you do so repeatedly,” explained Dr. Winickoff, who is also a professor at Harvard Medical School. “You touch the cartridge. You put it next to your face. You are spreading whatever is in your hand into your body. At the same time, many of my patients who smoke or vape have increased coughing or expectorating. And that’s a recipe for increased spread.”

Studies already amply show that cigarette smoking weakens the immune system and compromises lung function. Research into the health effects of vaping is limited because the devices are relatively new, but studies suggest that e-cigarettes may cause inflammation in the airways and lungs.

Flavored tobacco products, which teenagers and young adults find particularly alluring, can exacerbate lung infections, studies have found. Smokers and vapers, then, may be more susceptible to coronavirus infection, the Massachusetts advisory emphasizes, and once infected, such patients might also have a tougher time resisting an attack of Covid-19. Studies in mice have shown that vape-exposed mice are more susceptible to viral and bacterial infections, noted Robert Tarran, a professor of cell biology and physiology at the University of North Carolina.

Some people have questioned whether unexpectedly high numbers of younger people who have become seriously ill with Covid-19 are connected in some way with their predilection for vaping and marijuana.

“I am a firm believer that one plus one equals two. Until I have the evidence to believe otherwise, I believe it is critically important for us to help people quit inhaling anything into their lungs that could be causing any type of inflammation, as the coronavirus will only find an inviting environment otherwise,” said Dr. Carolyn Dresler, a former associate director of medical and health sciences for the Center for Tobacco Products at the Food and Drug Administration, during a webinar last week for Action on Smoking and Health, an international nonprofit group.

A recent study in the New England Journal of Medicine found that Chinese coronavirus patients who smoked were more than twice as likely as those who didn’t to have severe infections from Covid-19. And smoking has been identified as a factor in patients who became ill in 2012 with MERS, another coronavirus.

Another signal points to the vulnerability of smokers to this coronavirus. The virus seems to attack the body by attaching to a binding receptor called angiotensin-converting enzyme-2, or ACE-2. Tobacco use may increase the expression of ACE-2. That is why doctors and researchers speculate that smokers may become infected with more copies of the virus than other patients.

About 34 million adult Americans smoke cigarettes, according to recent data, and some

five million middle- and high-school students report having vaped nicotine and marijuana products.

A frightening outbreak of life-threatening lung illnesses tied to vaping last summer was eventually tied to vaping marijuana oils that contained the additive vitamin E acetate. But doctors say at least 15 percent of the patients reported having vaped only nicotine products.

Dr. Winickoff, a pediatrician, said that prudence about marijuana products was also advisable: "Inhaling combusted or vaped cannabis products can damage lung cells, may increase viral replication, and does affect the ability to fight off infection," he said. "Clean air is what the lungs should be inhaling, especially during a global pandemic."

Last month, the New York State Academy of Family Physicians called for a ban on sales of tobacco and e-cigarettes in the state during the pandemic. Already smoke shops are being shut down in many states because they are not deemed to be "essential" businesses. But some public health officials note that other retailers that sell cigarettes and vaping devices, such as gas stations and grocery stores, are still permitted to do so.

In defending such bans, public health experts say that behaviors associated with these products can provoke the spread of the virus. Wafting smoke and vapor may contain virus particles. Tobacco chewers tend to spit on the street. People often share e-cigarettes and cigarettes. And in using the products, consumers touch their faces frequently, increasing both their chances of becoming infected and then transmitting the virus.

One pushback to such bans, similar to that echoed among decisions to categorize wine and spirits as "essential" and permit their sales, is that so many people are addicted to cigarettes and e-cigarettes that they would be immediately thrown into the miseries of withdrawal.

But Dr. Winickoff of Harvard noted that it is nicotine that people are addicted to, not cigarettes or e-cigarettes per se.

"Use the nicotine patch for a baseline level of nicotine and then add in nicotine gum or lozenge for breakthrough cravings," he said. "That's the best way to use those products. Combining them will quadruple your chances of success."

Dr. Alicia Casey, who directs the pulmonary vaping program at Boston Children's Hospital, noted that one obstacle that had prevented her teenage patients from quitting was the omnipresence of the devices at school and parties. She had hoped that the enforced social distancing would help them quit.

"But I do often see that they're more anxious now, and they're vaping more frequently," she said. "If parents notice that happening, they should speak with their kids about the risks of Covid-19 and other pulmonary complications to vapers."

"I had a couple of teenagers this winter who had more trouble with influenza than they should have," Dr. Casey continued. "Since Covid-19 can be similar to a severe influenza, I worry about those underlying lung issues from vaping."

Sheila Kaplan contributed reporting.

Updated April 4, 2020

Should I wear a mask?

The C.D.C. has recommended that all Americans wear cloth masks if they go out in public. This is a shift in federal guidance reflecting new concerns that the coronavirus is being spread by infected people who have no symptoms. Until now, the C.D.C., like the W.H.O., has advised that ordinary people don't need to wear masks unless they are sick and coughing. Part of the reason was to preserve medical-grade masks for health care workers who desperately need them at a time when they are in continuously short supply. Masks don't replace hand washing and social distancing.

What should I do if I feel sick?

If you've been exposed to the coronavirus or think you have, and have a fever or symptoms like a cough or difficulty breathing, call a doctor. They should give you advice on whether you should be tested, how to get tested, and how to seek medical treatment without potentially infecting or exposing others.

How do I get tested?

If you're sick and you think you've been exposed to the new coronavirus, the C.D.C. recommends that you call your healthcare provider and explain your symptoms and fears. They will decide if you need to be tested. Keep in mind that there's a chance — because of a lack of testing kits or because you're asymptomatic, for instance — you won't be able to get tested.

How does coronavirus spread?

It seems to spread very easily from person to person, especially in homes, hospitals and other confined spaces. The pathogen can be carried on tiny respiratory droplets that fall as they are coughed or sneezed out. It may also be transmitted when we touch a contaminated surface and then touch our face.

Is there a vaccine yet?

No. The first testing in humans of an experimental vaccine began in mid-March. Such rapid development of a potential vaccine is unprecedented, but even if it is proved safe and effective, it probably will not be available for 12 to 18 months.

What makes this outbreak so different?

Unlike the flu, there is no known treatment or vaccine, and little is known about this particular virus so far. It seems to be more lethal than the flu, but the numbers are still uncertain. And it hits the elderly and those with underlying conditions — not just those with respiratory diseases — particularly hard.

What if somebody in my family gets sick?

If the family member doesn't need hospitalization and can be cared for at home, you should help him or her with basic needs and monitor the symptoms, while also keeping as much distance as possible, according to guidelines issued by the C.D.C. If there's space, the sick family member should stay in a separate room and use a separate bathroom. If masks are available, both the sick person and the caregiver should wear them when the caregiver enters the room. Make sure not to share any dishes or other household items and to regularly clean surfaces like counters, doorknobs, toilets and tables. Don't forget to wash your hands frequently.

Should I stock up on groceries?

Plan two weeks of meals if possible. But people should not hoard food or supplies. Despite the empty shelves, the supply chain remains strong. And remember to wipe the handle of the grocery cart with a disinfecting wipe and wash your hands as soon as you get home.

Can I go to the park?

Yes, but make sure you keep six feet of distance between you and people who don't live in your home. Even if you just hang out in a park, rather than go for a jog or a walk, getting some fresh air, and hopefully sunshine, is a good idea.

ACE2 Receptor Expression and Severe Acute Respiratory Syndrome Coronavirus Infection Depend on Differentiation of Human Airway Epithelia

Hong Peng Jia,¹ Dwight C. Look,² Lei Shi,² Melissa Hickey,¹ Lecia Pewe,¹ Jason Netland,¹ Michael Farzan,³ Christine Wohlford-Lenane,¹ Stanley Perlman,¹ and Paul B. McCray, Jr.^{1,*}

Departments of Pediatrics¹ and Internal Medicine,² Carver College of Medicine, University of Iowa, Iowa City, Iowa 52242, and Department of Microbiology and Molecular Genetics, Harvard University, Cambridge, Massachusetts 02138³

Received 16 June 2005/Accepted 14 September 2005

Studies of patients with severe acute respiratory syndrome (SARS) demonstrate that the respiratory tract is a major site of SARS-coronavirus (CoV) infection and disease morbidity. We studied host-pathogen interactions using native lung tissue and a model of well-differentiated cultures of primary human airway epithelia. Angiotensin converting enzyme 2 (ACE2), the receptor for both the SARS-CoV and the related human respiratory coronavirus NL63, was expressed in human airway epithelia as well as lung parenchyma. As assessed by immunofluorescence staining and membrane biotinylation, ACE2 protein was more abundantly expressed on the apical than the basolateral surface of polarized airway epithelia. Interestingly, ACE2 expression positively correlated with the differentiation state of epithelia. Undifferentiated cells expressing little ACE2 were poorly infected with SARS-CoV, while well-differentiated cells expressing more ACE2 were readily infected. Expression of ACE2 in poorly differentiated epithelia facilitated SARS spike (S) protein-pseudotyped virus entry. Consistent with the expression pattern of ACE2, the entry of SARS-CoV or a lentivirus pseudotyped with SARS-CoV S protein in differentiated epithelia was more efficient when applied to the apical surface. Furthermore, SARS-CoV replicated in polarized epithelia and preferentially exited via the apical surface. The results indicate that infection of human airway epithelia by SARS coronavirus correlates with the state of cell differentiation and ACE2 expression and localization. These findings have implications for understanding disease pathogenesis associated with SARS-CoV and NL63 infections.

Severe acute respiratory syndrome (SARS) emerged as a regional and global health threat in 2002–2003, resulting in approximately 800 deaths (5). An intense, cooperative worldwide effort rapidly led to the identification of the disease-causing agent as a novel SARS coronavirus (CoV) (18, 32) and the subsequent complete sequencing of the viral genome (24, 37). The SARS-CoV genome encodes 14 putative open reading frames encoding 28 potential proteins, and the functions of many of these proteins are not known. While the incidence of new cases of SARS waned in 2003–2004, many aspects of SARS disease pathogenesis and host-pathogen interactions remain unsolved.

Limited human pathological studies demonstrate that the respiratory tract is a major site of SARS-CoV infection and morbidity (8, 30). Two previously recognized human coronaviruses (HCoV-OC43 and HCoV-229E) cause ~30% of upper respiratory tract infections (14, 28), and, recently, two additional human coronaviruses, HCoV-NL63 (42) and HKU1 (46), were identified in association with bronchiolitis and pneumonia, respectively. Epidemiologic data suggest that infection with NL63 is common, as most adults have neutralizing antibodies to the virus (12). Limited studies of these other human coronaviruses indicate that they infect respiratory epithelia (2, 4, 44). Little is known regarding the initial steps of SARS-CoV

interaction with the host cells in the respiratory tract, such as the cell types in which primary viral infection and replication occur. Viral RNA has been localized to cells of the conducting airways and alveoli by *in situ* hybridization in SARS postmortem samples (40). Experimental evidence in several animal models, including nonhuman primates (7, 19, 27, 38), mice (9, 13), ferrets (25), and Syrian hamsters (34) indicates that direct application of SARS-CoV to the respiratory tract results in pulmonary infection. Furthermore, epidemiologic analysis of a Toronto SARS outbreak supports the hypothesis that the virus is transmitted by respiratory droplets (49). Thus, it appears likely that interactions between SARS-CoV and respiratory epithelia play an important role in the genesis of SARS.

The cellular receptors mediating binding and entry have been identified for some coronaviruses associated with human disease. HCoV-229E uses CD13 as a receptor (48). The cellular receptors for HCoV-OC43 and HKU1 are currently unknown. Recently, angiotensin converting enzyme 2 (ACE2) was identified as a receptor for both SARS-CoV (21) and NL63 (12). ACE2 is a membrane-associated aminopeptidase expressed in vascular endothelia, renal and cardiovascular tissue, and epithelia of the small intestine and testes (6, 10, 11). A region of the extracellular portion of ACE2 that includes the first α -helix and lysine 353 and proximal residues of the N terminus of β -sheet 5 interacts with high affinity to the receptor binding domain of the SARS-CoV S glycoprotein (22).

Several unanswered questions remain regarding ACE2 expression in human respiratory epithelia and its role as a receptor for SARS-CoV. These include the identification of the

* Corresponding author. Mailing address: Department of Pediatrics, 240-G EMRB, Carver College of Medicine, University of Iowa, Iowa City, IA 52242. Phone: (319) 335-6844. Fax: (319) 335-6925. E-mail: paul-mccray@uiowa.edu.

specific epithelial cell types expressing ACE2, the polarity of ACE2 expression, and whether SARS-CoV infection of respiratory epithelia is ACE2-dependent. Here we investigate interactions between SARS-CoV and human airway epithelia using native tissue and a primary culture model of polarized, well-differentiated tracheal and bronchial epithelia. Our findings indicate that the state of cell differentiation and ACE2 expression levels are both important determinants of the susceptibility of human airway epithelia to infection.

MATERIALS AND METHODS

Epithelial cell culture. Primary cultures of human airway epithelia were prepared from trachea or bronchi cells and grown at the air-liquid interface (ALI) on collagen-coated porous filters as described previously (17). In select experiments, the apical surface of primary cells was submerged under 500 μ l of cell culture medium for 7 days to induce dedifferentiation or grown in nonpolarized fashion on tissue culture plastic. This study was approved by the Institutional Review Board at the University of Iowa. A549 cells (ATCC CCL-185) were maintained in Dulbecco's modified Eagle's medium/F12 (Gibco) containing 10% fetal bovine serum, penicillin (100 U/ml), and streptomycin (100 mg/ml).

Immunoblot analysis. Cells or tissues were lysed in 0.1% Triton X-100 in phosphate-buffered saline (PBS), and total protein was separated on a sodium dodecyl sulfate-7.5% polyacrylamide gel electrophoresis gel and transferred to polyvinylidene difluoride membrane. Goat anti-ACE2 polyclonal primary antibody (catalog no. AF933, R & D Systems, Minneapolis, MN), horseradish peroxidase-conjugated donkey anti-goat secondary antibody, mouse anti-foxj1 monoclonal primary antibody (gift of S. Brody, Washington University), and a horseradish peroxidase-conjugated goat anti-mouse secondary antibody were used. Primary antibody binding was visualized using SuperSignal chemiluminescent substrate (Pierce, Rockford, IL).

Immunofluorescence staining. Airway epithelia were fixed in 4% paraformaldehyde for 5 min at room temperature and washed with PBS. Five percent bovine serum albumin in PBS was used to block nonspecific antibody binding. An anti-ACE2 monoclonal antibody (MAB933; R & D Systems, Minneapolis, MN) was applied to cells (both apical and basolateral surfaces for air-liquid interface-cultured cells). Epithelia were then incubated at 37°C for 1 h and again washed with PBS. Rabbit anti-mouse fluorescein isothiocyanate-conjugated secondary antibody (F-4143; Sigma, St. Louis, MO) was added to cells and incubated at 4°C overnight. Cells were then washed with PBS, and a Cy3-labeled mouse anti- β -tubulin IV monoclonal antibody (C-4585; Sigma) was added. Cells were incubated at 37°C for 1 h, followed by PBS washes, and then mounted with DAPI (4',6'-diamidino-2-phenylindole) VectaShield (Vector Labs, Burlingame, CA). Nuclei were stained with To-pro-3 (T3605; Sigma, St. Louis, MO). The SARS-CoV nsp1 protein was localized in cells fixed with 100% methanol using a rabbit polyclonal anti-nsp1 primary antibody (gift of M. Denison) (33) and a mouse anti-rabbit fluorescein isothiocyanate-conjugated secondary antibody (catalog no. A11088, Molecular Probes, Eugene, OR).

Surface biotinylation. The apical or basolateral surfaces of airway epithelia were treated with 1 mg/ml *N*-hydroxysulfosuccinimidobiotin (Pierce, Rockford, IL) in PBS for 30 min at 25°C. The epithelial surface was washed and then incubated with 100 mM glycine in PBS for 20 min at 25°C to quench unreacted biotin. Epithelial protein lysates were prepared by sonication in lysis buffer, and biotinylated proteins were precipitated using neutravidin covalently linked to immobilized diaminodipropylamine (Pierce). Biotinylated proteins were released in 8% sodium dodecyl sulfate-containing loading buffer, boiled, and analyzed by immunoblotting for ACE2. Erb2 was detected as a control basolateral membrane marker (43) using rabbit polyclonal anti-c-erbB2 antibody (Dako Corporation, Carpinteria, CA).

Scanning electron microscopy (SEM). Epithelia were fixed in 2.5% glutaraldehyde in Na cacodylate buffer for 30 min and rinsed with 0.1 M Na cacodylate buffer three times. Samples were postfixed in 1% OsO₄ for 1 h and sequentially rinsed with 0.1 M Na cacodylate buffer and H₂O. Samples were then serially dehydrated using 25% to 100% ethanol. After critical-point drying, samples were mounted on stubs, sputter coated, and examined using a Hitachi F-4000 electron microscope.

Real-time reverse transcription-PCR mRNA analysis. Total cellular RNA was isolated using TRI-Reagent (MRC, Cincinnati, OH) or a commercial spin column isolation kit (Stratagene, La Jolla, CA), and 1 μ g was reverse transcribed using a reverse transcription (RT)-PCR kit (Ambion, Austin, TX). An aliquot of cDNA was subjected to PCR using an iCycler iQ fluorescence thermocycler

(Bio-Rad, Hercules, CA) with SYBR green I DNA dye (Molecular Probes, Eugene, OR) and Platinum Taq DNA polymerase (iQ SYBR green Supermix kit, Bio-Rad). PCR conditions included denaturation at 95°C for 3 min and then for 35 cycles of 94°C for 30 s, 60°C for 30 s, and 72°C for 30 s, followed by 5 min at 72°C for elongation. The following primers were used: (i) human ACE2 forward 5'-GGACCCAGGAAATGTTTCAGA-3' and reverse 5'-GGCTGCAGA AAGTGACATGA-3', (ii) SARS-CoV N gene forward/leader 5'-ATATTAGGT TTTTACCCAGG-3' and reverse 5'-CTTGCCCCATTGCGTCCTCC-3', (iii) SARS-CoV S gene forward/leader 5'-ATATTAGGT TTTTACCCAGG-3' and reverse 5'-CTCTGAGGGAACAACCCTG-3', and (iv) human hypoxanthine phosphoribosyltransferase (HPRT) forward 5'-CCTCATGGACTGATTATG GAC-3' and reverse 5'-CAGATTCAACTTGCCTCATC-3'. Fluorescence data was captured during the 10-s dwell to ensure that primer dimers were not contributing to the fluorescence signal, and specificity of the amplification was confirmed using melting curve analysis. Data was collected and recorded by iCycler iQ software (Bio-Rad) and initially determined as a function of threshold cycle (*C_T*). Levels of mRNA were expressed relative to control HPRT levels, which were calculated as 2 ^{ΔC_T} . In some samples, PCR products were visualized on 2% agarose gels with ethidium bromide.

Adenoviral vectors. E1-deleted replication incompetent adenoviral vectors expressing human ACE2, *Escherichia coli* β -galactosidase, and foxj1 under the control of the cytomegalovirus promoter were produced as previously described (1).

Preparation of SARS S protein-pseudotyped lentivirus and infection of airway epithelia. The SARS-CoV S protein cDNA (Urbani strain "S-H2," as described reference 21) was used to pseudotype feline immunodeficiency virus (FIV) expressing a nuclear-targeted β -galactosidase by using previously described methods (45). The virus was concentrated 250-fold by centrifugation, and titers were determined on HT1080 cells, obtaining titers of $\sim 2 \times 10^5$ to 4×10^6 transducing units/ml. Well-differentiated human airway epithelia were transduced with the pseudotyped FIV by applying 100 μ l of solution to the apical surface of airway epithelia. After 1 h of incubation at 37°C, virus was removed and cells were incubated at 37°C for 2 days. To infect epithelia from the basolateral side, the Millicell insert was turned over, and virus was applied to the basolateral surface for 1 h in 100 μ l of medium. Following the 1-h infection, virus was removed and the insert was turned upright and incubated at 37°C in 5% CO₂ for 2 days.

β -Galactosidase activity assays. The Galacto-Light chemiluminescent reporter assay (Tropix, Bedford, MA) was used to quantify β -galactosidase activity following the manufacturer's protocol. Relative light units were quantified using a luminometer (Monolight 3010; Pharmingen, San Diego, CA) and standardized to total protein in the sample.

Preparation of wild-type SARS-CoV and infection of airway epithelia. SARS-CoV (Urbani strain) was produced in Vero E6 cells under BSL3 containment conditions. Virus titers were determined on Vero E6 cells with typical yields of $\sim 4 \times 10^6$ PFU/ml. Epithelia derived from three donors were infected in duplicate with SARS-CoV from the apical surface (multiplicity of infection [MOI], 0.8). Following a 30-min incubation at 37°C, virus was removed and 10 washes with PBS were performed. A sample was collected by adding and removing 500 μ l of medium from the apical side of one epithelium from each donor. A total of 500 μ l of medium was added to the basolateral side of the remaining epithelia, and 24 h later, samples were collected for titer determinations.

RESULTS

ACE2 expression in human airway epithelia. ACE2 serves as the SARS-CoV receptor, at least for tissue culture cell entry (21). To determine if ACE2 is also the SARS-CoV receptor in the respiratory tract, we first looked for evidence of ACE2 protein expression in human lung tissue by Western blotting. An immunoreactive band consistent with the glycosylated form of ACE2 was identified in lysates from human airway and distal lung tissue (Fig. 1A). However, the cell type expressing ACE2 could not be identified in this experiment, as both endothelial and epithelial cells can express ACE2. Accordingly, we next evaluated ACE2 protein expression in well-differentiated primary cultures of airway epithelia using immunohistochemistry and observed airway epithelial cell expression, with the most abundant signal for ACE2 on the apical rather than the basolateral surface (Fig. 1B). Furthermore, the signal intensity was strongest on ciliated cells, as demonstrated by colocalization




FIG. 1. ACE2 is expressed on human airway epithelia. (A) ACE2 protein levels were determined using immunoblot analysis of extracts from human airway and alveolar tissue. The control is recombinant ACE2 released into the supernatant from A549 cells infected with an adenoviral vector expressing human ACE2. The positions of ACE2 and α -tubulin are indicated by arrows. MW, molecular weight in thousands. (B) ACE2 protein location in polarized human airway epithelia was determined using immunofluorescence staining for ACE2 (green), β -tubulin IV (red), and nuclear DAPI (blue). Confocal fluorescence photomicroscopic images are presented en face (top) and from vertical sections (bottom). Colocalization is shown by yellow in the merged images. Bar, 10 μ m. (C) ACE2 protein location in polarized human airway epithelia was determined by selective apical or basolateral biotinylation, immunoprecipitation of biotinylated surface proteins, and immunoblot analysis for ACE2 or control basolateral erbB2. MW, molecular weight in thousands. The positions of ACE2 and erbB2 are indicated by arrows.

with the β -tubulin IV marker of cilia (23), suggesting that ciliated cells express ACE2 abundantly. To confirm a polar distribution of ACE2 in differentiated epithelia, selective apical or basolateral surface biotinylation with subsequent precipitation was performed (Fig. 1C). Immunoblot analysis of precipitated proteins confirmed that ACE2 is expressed in greater abundance on the apical surface of conducting airway epithelia, although in some experiments a weak ACE2 signal was also detected basolaterally. In contrast, ErbB2, the receptor for heregulin- α , was more abundant on the basolateral surface as previously reported (43), confirming selective biotinylation.

Results from polarized epithelia suggested that ACE2 expression might depend on the state of cellular differentiation. To validate a model to test this hypothesis, we used SEM to compare the apical surface morphology of well-differentiated epithelia with that of well-differentiated cells subsequently grown with medium present on their apical surfaces for 7 days. Of note, submersion of the apical surfaces of primary cells caused loss of cilia (Fig. 2A). Loss of this important marker of cell differentiation with resubmersion was associated with markedly diminished expression of ACE2 mRNA and protein

(Fig. 2B and C). In contrast to results in polarized epithelia, poorly differentiated primary human tracheobronchial epithelia (hTBE) or A549 cells grown on tissue culture plastic expressed little ACE2 mRNA or protein. Interestingly, *foxf1*, a transcription factor required for a well-differentiated ciliated epithelia phenotype (3) was also coordinately expressed with ACE2, indicating that ACE2 positively correlates with the state of epithelial differentiation. We also asked whether *foxf1* might directly regulate ACE2 expression in airway epithelia. Primary tracheobronchial cells grown in submersion culture were transduced with an adenoviral vector expressing ACE2, a negative-control β -galactosidase, or *foxf1*. Only transduction with the ACE2 vector conferred ACE2 expression, suggesting that *foxf1* expression alone does not regulate ACE2 (Fig. 2D and data not shown).

SARS-CoV infection of human airway epithelia. To evaluate the polarity of entry of the SARS-CoV in airway epithelia, we prepared FIV virions pseudotyped with SARS S protein. The ACE2 dependence of transduction with SARS S protein-pseudotyped FIV virions was first evaluated on 293 cells with or without cotransfection with human ACE2 cDNA. We ob-




FIG. 2. ACE2 expression is associated with airway epithelial cell differentiation. (A) Ciliated epithelial cell differentiation in cultures of primary airway epithelial cells under air-liquid interface or resubmerged conditions was verified by SEM of the apical epithelial surface.

served that 293 cell transduction with this vector was almost completely ACE2-dependent (Fig. 3A). To establish the ACE2 dependence of human airway epithelia for SARS-CoV, we transduced poorly differentiated A549 cells and submerged primary hTBE cells that do not express constitutive ACE2 with increasing amounts of an adenoviral vector expressing human ACE2. After 48 h, SARS-CoV S protein-pseudotyped-FIV was applied to the apical surface at an MOI of 0.1 (based on HT1080 titers). There was an inoculum-dependent increase in the transduction of cells that expressed ACE2 (Fig. 3B). S protein-pseudotyped FIV was then used to contrast the efficiency of entry in A549 cells, poorly differentiated (submerged) human airway epithelia, and well-differentiated (ALI) epithelia. Only well-differentiated epithelial cells showed significant β -galactosidase expression following transduction (Fig. 3C). We next applied the pseudotyped virus to the apical or basolateral surfaces of well-differentiated primary cultures of human airway epithelia to investigate whether the virus preferentially entered from one cell surface. After 2 days, the cells were harvested and entry was evaluated by β -galactosidase activity. Transduction of human airway epithelia by the S protein-pseudotyped virions occurred more efficiently when applied from the apical rather than the basolateral surface (Fig. 3D). This pattern of entry correlates with ACE2 expression on polarized cells (Fig. 1). In contrast, FIV pseudotyped with the vesicular stomatitis virus-G envelope entered polarized cells better from the basolateral surface.

We went on to perform select experiments using wild-type SARS-CoV (Urbani strain). Using protocols similar to those outlined for Fig. 3, we evaluated the ability of SARS-CoV to infect multiple human airway epithelial cell culture models. Under BSL3 containment, we applied the virus to A549 cells, poorly differentiated (submerged) primary cultures of airway epithelia, or well-differentiated (ALI) human airway epithelia at an MOI of 0.8. A549 and hTBE cells cultured under submerged conditions expressed little detectable SARS-CoV N or S gene mRNA after infection (Fig. 4A). In contrast, in well-differentiated cells infected with SARS-CoV from the apical surface, the N and S gene mRNAs were detected at high levels. We confirmed that the gene products detected in real-time RT-PCR assays were generated from new SARS-CoV mRNA templates rather than viral genome by verifying the appropriate size of the amplified products (Fig. 4B). The primers used

Bar, 10 μ m. (B) ACE2 mRNA levels were determined using real-time RT-PCR analysis of samples from A549 cells or primary hTBE cells cultured under undifferentiating submerged (Sub), differentiating ALI, or resubmerged (Resub) conditions. Values are expressed as mean mRNA levels relative to control HPRT mRNA levels plus or minus standard deviations (SD) ($n = 3$), and the asterisk indicates a significant difference in mRNA levels between air-liquid interface and resubmerged conditions. (C) ACE2 protein levels were determined using immunoblot analysis of extracts from A549 or primary hTBE cells. The positions of ACE2, foxj1 (to verify epithelial cell differentiation status), and β -actin are indicated by arrows. MW, molecular weight in thousands. (D) ACE2 protein levels were determined using immunoblot analysis of extracts from hTBE cells under submerged conditions that were infected with a recombinant adenoviral vector that expressed ACE2, control transgene (β -galactosidase), or foxj1. MW, molecular weight in thousands.




FIG. 3. SARS-CoV S protein-pseudotyped FIV infects differentiated airway epithelia best from the apical surface. (A) β -galactosidase levels were determined by enzyme activity in 293 cells transfected with a plasmid expressing control (Ctl) transgene or human ACE2 and then infected with SARS-S protein-pseudotyped FIV expressing β -galactosidase. ND, not detected. (B) β -galactosidase levels were determined in A549 cells (black bars) or primary hTBE cultured under submerged conditions (white bars) that were first infected with an adenoviral

included a forward primer in the conserved SARS CoV 5' leader sequence and gene-specific reverse primers. These results suggest that SARS-CoV infects undifferentiated human airway epithelial cells poorly or not at all, while well-differentiated airway epithelia are susceptible.

To document that SARS-CoV productively infects human airway epithelia, we applied the virus to the apical surface of well-differentiated human airway epithelia at an MOI of ~ 0.8 for 30 min and then measured the release of virus 24 h later. As shown in Table 1, these results indicate that, following apical application of SARS-CoV, a productive infection occurred and virus was preferentially released apically. We confirmed SARS-CoV infection of polarized epithelia by immunostaining cells for the SARS-CoV nsp1 protein 24 h following infection. Confocal microscopy revealed viral nsp1 protein in the cytoplasm, consistent with replication complexes, following apical application of the virus (Fig. 4C). Control, noninfected cells showed no staining. The infection of permissive Vero E6 cells showed intense cytoplasmic staining only in the presence of SARS-CoV infection (data not shown). To better define the cell types infected by SARS-CoV in this model, we colocalized the nsp1 and β -tubulin IV proteins (Fig. 4D). Nsp1 staining was observed in perinuclear regions and distributed throughout the cytoplasm. In addition, we observed some areas of colocalization of nsp1 and β -tubulin IV, suggesting that replication complexes may assemble in the cytoplasm near or within cilia. These findings indicate that ciliated cells are the predominant cell type infected by SARS-CoV in well-differentiated airway epithelia.

DISCUSSION

We report the novel observation that SARS-CoV infection of human airway epithelia is dependent upon the state of epithelial differentiation and ACE2 mRNA and protein expression. ACE2 is more abundantly expressed on the apical surface of polarized epithelia, and we show for the first time that well-differentiated cells support viral replication with viral entry and egress occurring primarily from the apical surface. Thus, SARS-CoV preferentially infects well-differentiated ciliated epithelial cells expressing ACE2. Since ACE2 is also the receptor for the coronavirus NL63 (12), these findings are relevant to the biology of infection with this more common human pathogen.

ACE2 expression in human tissues correlates with known sites of infection, including lung and intestine (6, 10, 11). ACE2 is an ectoenzyme that converts angiotensin II to angio-

vector expressing ACE2 at the indicated MOI and then infected with SARS-S protein-pseudotyped FIV expressing β -galactosidase. (C) β -Galactosidase levels determined in extracts from A549 cells or primary hTBE cultured under submerged or ALI conditions that were infected from the apical surface with SARS-S protein-pseudotyped FIV expressing β -galactosidase. (D) β -galactosidase levels determined in primary hTBE cultured under ALI conditions that were infected from the apical or basolateral surface with vesicular stomatitis virus-G or SARS-S protein-pseudotyped FIV. In panels A through D, values are expressed as means plus or minus SD ($n = 4$ to 6) and a significant difference from levels on uninfected cells (A and B), hTBE cells cultured under submerged conditions (C), or cells infected from the apical surface (D) is indicated by an asterisk. RLU, relative light units.




FIG. 4. Infection of differentiated airway epithelia by SARS-CoV. (A) SARS-CoV N and S gene mRNA levels were determined using real-time RT-PCR analysis of A549 cells or primary hTBE cultured under submerged or ALI conditions and infected with SARS-CoV from the apical surface at an MOI of 0.8 for 24 h. Values are expressed as mean mRNA levels relative to control HPRT mRNA levels plus or minus SD ($n = 2$). ND, not detected. An asterisk indicates a significant difference in mRNA levels between submerged and ALI conditions. (B) PCR products in panel A for hTBE cells cultured under ALI conditions were visualized by ethidium bromide. bp, base pairs. (C) SARS-CoV nsp1 replicase protein location in polarized human airway epithelia that were left uninfected or infected from the apical or basolateral side with SARS-CoV. Twenty-four hours following infection with SARS-CoV viral replication, complexes were localized using immunofluorescence staining for nsp1 (green) and nuclear To-pro-3 (red). Bar, 50 μ m. (D) Colocalization of SARS-CoV nsp1 protein and cilia in polarized human airway epithelia. Airway epithelia were infected as described in the legend for Fig. 4C and then fixed and immunostained for nsp1 (green) or β -tubulin IV (red) as a marker for ciliated cells. The merged image shows colocalization of nsp1 and β -tubulin, indicating that the predominant infected cell types were ciliated epithelia. Bar, 10 μ m.

tensin (1–7) (41), but its physiologic role in the airways is currently unknown. The predominant apical distribution of ACE2 suggests that the enzyme may be available to cleave peptides at the mucosal surface of the airway, but the native substrates in the lung have not yet been identified.

Epidemiologic data indicate that SARS-CoV is spread by respiratory droplets and contact (49). While such findings suggest that the virus enters the host through the mucosa of the respiratory tract and the eyes, many details of the initial steps of respiratory cell infection by SARS-CoV in humans are

TABLE 1. Polar release of SARS-CoV following apical application to airway epithelia^a

Virion egress type	Egress value (PFU/ml) for specimen no.:		
	1	2	3
Apical	2.5×10^4	5×10^4	3×10^4
Basolateral	15	20	5

^a Urbani strain SARS-CoV at an MOI of 0.8 was applied to the apical surface of well-differentiated epithelia from three different human donors. Virion egress was assayed 24 h later by determining the titers for Vero E6 cells.

poorly understood. Limited human pathology data, primarily autopsy studies from SARS patients with severe disease and secondary complications, including respiratory failure, indicate the presence of virus in both proximal and distal pulmonary epithelia (40). Most data from human respiratory tissue from SARS patients was obtained two or more weeks following disease onset (8, 15, 20, 40). Lung tissue from such patients exhibits changes of diffuse alveolar damage, desquamated epithelial cells, type II cell hyperplasia, fibrin and collagen deposits in the alveolar space, increased mononuclear infiltrates in the interstitium, and, in some cases, the presence of multinucleated syncytial cells. Such changes reflect the combined effects of primary infection, host immune responses, and therapeutic interventions.

Human ACE2 appears necessary and sufficient to serve as a receptor for SARS-CoV (21). While both dendritic-cell-specific ICAM3-grabbing nonintegrin (DC-SIGN; CD209) and DC-SIGNR (L-SIGN, CD209L) can enhance SARS-CoV infection of ACE2 expressing cells, these proteins are not sufficient to support infection in the absence of ACE2 (16, 26, 47). Several recent reports using SARS-CoV or retroviral vectors pseudotyped with SARS S protein (31, 39, 47) (29) indicated that human airway epithelial cell lines were poorly transduced, an unexpected finding that raised questions regarding the ability of respiratory epithelia to support SARS-CoV infection. The present studies help explain these results. Since SARS-CoV infection of airway epithelia is ACE2-dependent, and ACE2 expression is greatest in well-differentiated cells, the low transduction efficiencies of nonpolarized, poorly differentiated cells are not unanticipated.

Our findings suggest that the epithelium of the conducting airways, the major site of respiratory droplet deposition, supports the replication of SARS-CoV. The observation that ACE2 complementation of poorly differentiated epithelia enhanced transduction with S protein-pseudotyped virions in a dose-dependent manner further supports its role as a receptor. In the setting of a productive infection of conducting airway epithelia, the apically released SARS-CoV might be removed by mucociliary clearance and gain access to the gastrointestinal tract. SARS-CoV infects cells in the gastrointestinal tract, and diarrhea is a clinical sign commonly observed in patients with SARS (5). Furthermore, the preferential apical exit pathway of virions would favor the spread of infection along the respiratory tract. While not a focus of this study, pathological data indicate that SARS-CoV infects type II pneumocytes (40). The infection and release of virus in this compartment with its close proximity to the pulmonary capillary bed might allow systemic spread of virus to distant organs, especially in the context of

inflammation and alveolar capillary leak. This pattern of apical infection and release of virus in polarized epithelia is reminiscent of transmissible porcine gastroenteritis virus (36) and HCoV-229E (44). In contrast, mouse hepatitis virus-A59 enters polarized cells from the apical surfaces and exits from the basolateral side (35).

In summary, studies in models of human airway epithelial differentiation and polarity reveal that SARS-CoV infects well-differentiated cells from the apical surface and preferentially exits from the apical side. These findings should also apply to the entry of NL63 in human airway epithelia. ACE2 expression in airway epithelia appears to be both necessary and sufficient for SARS-CoV infection. Airway epithelial expression of ACE2 is dynamic and associated with cellular differentiation, a finding that may underlie susceptibility to infection. The apical expression of ACE2 on epithelia indicates that this coronavirus receptor is accessible for topical application of receptor antagonists or inhibitors. To date, the factors regulating ACE2 expression have not been identified. Future studies of the ACE2 promoter and gene expression associated with cell differentiation may reveal regulators of ACE2 expression and subsequent SARS-CoV and NL63 susceptibility.

ACKNOWLEDGMENTS

We acknowledge the support of NIH PO1 AI060699-01.

We thank Jian Shao and Paola Vermeer for technical advice and assistance. We thank Steve Brody for supplying the antibodies against foxj1, an adenoviral vector expressing foxj1, and helpful discussions. We thank Carmen Halabi and Curt Sigmund for providing the human ACE2 cDNA. We also acknowledge the support of the Cell Culture and Gene Transfer Vector Cores, partially supported by the Center for Gene Therapy for Cystic Fibrosis (NIH P30 DK-54759) and the Cystic Fibrosis Foundation, for preparing airway epithelial cultures and adenoviral vectors.

REFERENCES


- Anderson, R. D., R. E. Haskell, H. Xia, B. J. Roessler, and B. L. Davidson. 2000. A simple method for the rapid generation of recombinant adenovirus vectors. *Gene Ther.* 7:1034–1038.
- Bradburne, A. F., M. L. Bynoe, and D. A. Tyrrell. 1967. Effects of a “new” human respiratory virus in volunteers. *Br. Med. J.* 3:767–769.
- Brody, S. L., X. H. Yan, M. K. Wuertel, S. K. Song, and S. D. Shapiro. 2000. Ciliogenesis and left-right axis defects in forkhead factor HFH-4-null mice. *Am. J. Respir. Cell Mol. Biol.* 23:45–51.
- Chilvers, M. A., M. McKean, A. Rutman, B. S. Myint, M. Silverman, and C. O’Callaghan. 2001. The effects of coronavirus on human nasal ciliated respiratory epithelium. *Eur. Respir. J.* 18:965–970.
- Donnelly, C. A., A. C. Ghani, G. M. Leung, A. J. Hedley, C. Fraser, S. Riley, L. J. Abu-Raddad, L. M. Ho, T. Q. Thach, P. Chau, K. P. Chan, T. H. Lam, L. Y. Tse, T. Tsang, S. H. Liu, J. H. Kong, E. M. Lau, N. M. Ferguson, and R. M. Anderson. 2003. Epidemiological determinants of spread of causal agent of severe acute respiratory syndrome in Hong Kong. *Lancet* 361:1761–1766.
- Donoghue, M., F. Hsieh, E. Baronas, K. Godbout, M. Gosselin, N. Stagliano, M. Donovan, B. Woolf, K. Robison, R. Jeyaseelan, R. E. Breitbart, and S. Acton. 2000. A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1–9. *Circ. Res.* 87:e1–e9. [Online.]
- Fouchier, R. A., T. Kuiken, M. Schutten, G. van Amerongen, G. J. van Doornum, B. G. van den Hoogen, M. Peiris, W. Lim, K. Stohr, and A. D. Osterhaus. 2003. Aetiology: Koch’s postulates fulfilled for SARS virus. *Nature* 423:240.
- Franks, T. J., P. Y. Chong, P. Chui, J. R. Galvin, R. M. Lourens, A. H. Reid, E. Selbs, C. P. McEvoy, C. D. Hayden, J. Fukuoka, J. K. Taubenberger, and W. D. Travis. 2003. Lung pathology of severe acute respiratory syndrome (SARS): a study of 8 autopsy cases from Singapore. *Hum. Pathol.* 34:743–748.
- Glass, W. G., K. Subbarao, B. Murphy, and P. M. Murphy. 2004. Mechanisms of host defense following severe acute respiratory syndrome-coronavirus (SARS-CoV) pulmonary infection of mice. *J. Immunol.* 173:4030–4039.
- Hamming, I., W. Timens, M. L. Bulthuis, A. T. Lely, G. J. Navis, and H. van Goor. 2004. Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. *J. Pathol.* 203:631–637.

11. Harmer, D., M. Gilbert, R. Borman, and K. L. Clark. 2002. Quantitative mRNA expression profiling of ACE 2, a novel homologue of angiotensin converting enzyme. *FEBS Lett.* 532:107–110.
12. Hofmann, H., P. Krzysztosf, L. van der Hoek, M. Geier, B. Berkhout, and S. Pohlmann. 2005. Human coronavirus NL63 employs the severe acute respiratory syndrome coronavirus receptor for cellular entry. *Proc. Natl. Acad. Sci. USA* 102:7988–7993.
13. Hogan, R. J., G. Gao, T. Rowe, P. Bell, D. Flieder, J. Paragas, G. P. Kobinger, N. A. Wivel, R. G. Crystal, J. Boyer, H. Feldmann, T. G. Voss, and J. M. Wilson. 2004. Resolution of primary severe acute respiratory syndrome-associated coronavirus infection requires Stat1. *J. Virol.* 78:11416–11421.
14. Holmes, K. V., and M. M. C. Lai. 1996. *Coronaviridae*: the viruses and their replication, p. 1075–1093. In B. N. Fields, D. M. Knipe, and P. M. Howley (ed.), *Fields virology*, 3rd ed. Lippincott-Raven Publishers, Philadelphia, Pa.
15. Hwang, D. M., D. W. Chamberlain, S. M. Poutanen, D. E. Low, S. L. Asa, and J. Butany. 2004. Pulmonary pathology of severe acute respiratory syndrome in Toronto. *Mod. Pathol.* 23:23.
16. Jeffers, S. A., S. M. Tusell, L. Gillim-Ross, E. M. Hemmila, J. E. Achenbach, G. J. Babcock, W. D. Thomas, Jr., L. B. Thackray, M. D. Young, R. J. Mason, D. M. Ambrosino, D. E. Wentworth, J. C. Demartini, and K. V. Holmes. 2004. CD209L (L-SIGN) is a receptor for severe acute respiratory syndrome coronavirus. *Proc. Natl. Acad. Sci. USA* 101:15748–15753. (First published 20 October 2004; 10.1073/pnas.0403812101.)
17. Karp, P. H., T. O. Moninger, S. P. Weber, T. S. Nesselhauf, J. L. Launspach, J. Zabner, and M. J. Welsh. 2002. An in vitro model of differentiated human airway epithelia. Methods for establishing primary cultures. *Methods Mol. Biol.* 188:115–137.
18. Ksiazek, T. G., D. Erdman, C. S. Goldsmith, S. R. Zaki, T. Peret, S. Emery, S. Tong, C. Urbani, B. A. Comer, W. Lim, P. E. Rollin, S. F. Dowell, A. E. Ling, C. D. Humphrey, W. J. Shieh, J. Guarnier, C. D. Paddock, P. Rota, B. Fields, J. DeRisi, J. Y. Yang, N. Cox, J. M. Hughes, J. W. LeDuc, W. J. Bellini, and L. J. Anderson. 2003. A novel coronavirus associated with severe acute respiratory syndrome. *N. Engl. J. Med.* 348:1953–1966.
19. Kuiken, T., R. A. Fouchier, M. Schutten, G. F. Rimmelzwaan, G. van Amerongen, D. van Riel, J. D. Laman, T. de Jong, G. van Doornum, W. Lim, A. E. Ling, P. K. Chan, J. S. Tam, M. C. Zambon, R. Gopal, C. Drosten, S. van der Werf, N. Escriou, J. C. Manuguerra, K. Stohr, J. S. Peiris, and A. D. Osterhaus. 2003. Newly discovered coronavirus as the primary cause of severe acute respiratory syndrome. *Lancet* 362:263–270.
20. Lang, Z., L. Zhang, S. Zhang, X. Meng, J. Li, C. Song, L. Sun, and Y. Zhou. 2003. Pathological study on severe acute respiratory syndrome. *Chin. Med. J. (Engl.)* 116:976–980.
21. Li, W., M. J. Moore, N. Vasilieva, J. Sui, S. K. Wong, M. A. Berne, M. Somasundaran, J. L. Sullivan, K. Luzuriaga, T. C. Greenough, H. Choe, and M. Farzan. 2003. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. *Nature* 426:450–454.
22. Li, W., C. Zhang, J. Sui, J. H. Kuhn, M. J. Moore, S. Luo, S. K. Wong, I. C. Huang, K. Xu, N. Vasilieva, A. Murakami, Y. He, W. A. Marasco, Y. Guan, H. Choe, and M. Farzan. 2005. Receptor and viral determinants of SARS-coronavirus adaptation to human ACE2. *EMBO J.* 24:1634–1643.
23. Look, D. C., M. J. Walter, M. R. Williamson, L. Pang, Y. You, J. N. Sreshta, J. E. Johnson, D. S. Zander, and S. L. Brody. 2001. Effects of paramyxoviral infection on airway epithelial cell Foxj1 expression, ciliogenesis, and mucociliary function. *Am. J. Pathol.* 159:2055–2069.
24. Marra, M. A., S. J. Jones, C. R. Astell, R. A. Holt, A. Brooks-Wilson, Y. S. Butterfield, J. Khattar, J. K. Asano, S. A. Barber, S. Y. Chan, A. Cloutier, S. M. Coughlin, D. Freeman, N. Ginn, O. L. Griffith, S. R. Leach, M. Mayo, H. McDonald, S. B. Montgomery, P. K. Pandoh, A. S. Petrescu, A. G. Robertson, J. E. Schein, A. Siddiqui, D. E. Smailis, J. M. Stott, G. S. Yang, F. Plummer, A. Andonov, H. Artsob, N. Bastien, K. Bernard, T. F. Booth, D. Bowness, M. Czub, M. Drebot, L. Fernando, R. Flick, M. Garbutt, M. Gray, A. Grolla, S. Jones, H. Feldmann, A. Meyers, A. Kabani, Y. Li, S. Normand, U. Stroher, G. A. Tipples, S. Tyler, R. Vogrig, D. Ward, B. Watson, R. C. Brunham, M. Krajden, M. Petric, D. M. Skowronski, C. Upton, and R. L. Roper. 2003. The genome sequence of the SARS-associated coronavirus. *Science* 300:1399–1404.
25. Martina, B. E., B. L. Haagmans, T. Kuiken, R. A. Fouchier, G. F. Rimmelzwaan, G. Van Amerongen, J. S. Peiris, W. Lim, and A. D. Osterhaus. 2003. Virology: SARS virus infection of cats and ferrets. *Nature* 425:915.
26. Marzi, A., T. Gramberg, G. Simmons, P. Moller, A. J. Rennekamp, M. Krumbiegel, M. Geier, J. Eisemann, N. Turza, B. Saunier, A. Steinkasserer, S. Becker, P. Bates, H. Hofmann, and S. Pohlmann. 2004. DC-SIGN and DC-SIGNR interact with the glycoprotein of Marburg virus and the S protein of severe acute respiratory syndrome coronavirus. *J. Virol.* 78:12090–12095.
27. McAuliffe, J., L. Vogel, A. Roberts, G. Fahle, S. Fischer, W. J. Shieh, E. Butler, S. Zaki, M. St Claire, B. Murphy, and K. Subbarao. 2004. Replication of SARS coronavirus administered into the respiratory tract of African Green rhesus and cynomolgus monkeys. *Virology* 330:8–15.
28. McIntosh, K., R. K. Chao, H. E. Krause, R. Wasil, H. E. Mocega, and M. A. Mufson. 1974. Coronavirus infection in acute lower respiratory tract disease of infants. *J. Infect. Dis.* 130:502–507.
29. Mossel, E. C., C. Huang, K. Narayanan, S. Makino, R. B. Tesh, and C. J. Peters. 2005. Exogenous ACE2 expression allows refractory cell lines to support severe acute respiratory syndrome coronavirus replication. *J. Virol.* 79:3846–3850.
30. Nicholls, J. M., L. L. Poon, K. C. Lee, W. F. Ng, S. T. Lai, C. Y. Leung, C. M. Chu, P. K. Hui, K. L. Mak, W. Lim, K. W. Yan, K. H. Chan, N. C. Tsang, Y. Guan, K. Y. Yuen, and J. S. Peiris. 2003. Lung pathology of fatal severe acute respiratory syndrome. *Lancet* 361:1773–1778.
31. Nie, Y., P. Wang, X. Shi, G. Wang, J. Chen, A. Zheng, W. Wang, Z. Wang, X. Qu, M. Luo, L. Tan, X. Song, X. Yin, M. Ding, and H. Deng. 2004. Highly infectious SARS-CoV pseudotyped virus reveals the cell tropism and its correlation with receptor expression. *Biochem. Biophys. Res. Commun.* 321:994–1000.
32. Poutanen, S. M., D. E. Low, B. Henry, S. Finkelstein, D. Rose, K. Green, R. Tellier, R. Draker, D. Adachi, M. Ayers, A. K. Chan, D. M. Skowronski, I. Salit, A. E. Simor, A. S. Slutsky, P. W. Doyle, M. Krajden, M. Petric, R. C. Brunham, and A. J. McGeer. 2003. Identification of severe acute respiratory syndrome in Canada. *N. Engl. J. Med.* 348:1995–2005.
33. Prentice, E., J. McAuliffe, X. Lu, K. Subbarao, and M. R. Denison. 2004. Identification and characterization of severe acute respiratory syndrome coronavirus replicase proteins. *J. Virol.* 78:9977–9986.
34. Roberts, A., L. Vogel, J. Guarnier, N. Hayes, B. Murphy, S. Zaki, and K. Subbarao. 2005. Severe acute respiratory syndrome coronavirus infection of golden Syrian hamsters. *J. Virol.* 79:503–511.
35. Rossen, J. W., W. F. Voorhout, M. C. Horzinek, A. van der Ende, G. J. Strous, and P. J. Rottier. 1995. MHV-A59 enters polarized murine epithelial cells through the apical surface but is released basolaterally. *Virology* 210:54–66.
36. Rossen, J. W., A., C. P. J. Bekker, W. F. Voorhout, G. J. A. M. Strous, A. van der Ende, and P. J. M. Rottier. 1994. Entry and release of transmissible gastroenteritis coronavirus are restricted to apical surfaces of polarized epithelial cells. *J. Virol.* 68:7966–7973.
37. Rota, P. A., M. S. Oberste, S. S. Monroe, W. A. Nix, R. Campagnoli, J. P. Icenogle, S. Penaranda, B. Bankamp, K. Maher, M. H. Chen, S. Tong, A. Tamin, L. Lowe, M. Frace, J. L. DeRisi, Q. Chen, D. Wang, D. D. Erdman, T. C. Peret, C. Burns, T. G. Ksiazek, P. E. Rollin, A. Sanchez, S. Liffick, B. Holloway, J. Limor, K. McCaustland, M. Olsen-Rasmussen, R. Fouchier, S. Gunther, A. D. Osterhaus, C. Drosten, M. A. Pallansch, L. J. Anderson, and W. J. Bellini. 2003. Characterization of a novel coronavirus associated with severe acute respiratory syndrome. *Science* 300:1394–1399.
38. Rowe, T., G. Gao, R. J. Hogan, R. G. Crystal, T. G. Voss, R. L. Grant, P. Bell, G. P. Kobinger, N. A. Wivel, and J. M. Wilson. 2004. Macaque model for severe acute respiratory syndrome. *J. Virol.* 78:11401–11404.
39. Simmons, G., J. D. Reeves, A. J. Rennekamp, S. M. Amberg, A. J. Piefer, and P. Bates. 2004. Characterization of severe acute respiratory syndrome-associated coronavirus (SARS-CoV) spike glycoprotein-mediated viral entry. *Proc. Natl. Acad. Sci. USA* 101:4240–4245.
40. To, K., J. H. Tong, P. K. Chan, F. W. Au, S. S. Chim, K. Allen Chan, J. L. Cheung, E. Y. Liu, G. M. Tse, A. W. Lo, Y. Dennis Lo, and H. Ng. 2004. Tissue and cellular tropism of the coronavirus associated with severe acute respiratory syndrome: an in-situ hybridization study of fatal cases. *J. Pathol.* 202:157–163.
41. Turner, A. J., J. A. Hiscox, and N. M. Hooper. 2004. ACE2: from vasopeptidase to SARS virus receptor. *Trends Pharmacol. Sci.* 25:291–294.
42. van der Hoek, L., K. Pyrc, M. F. Jebbink, W. Vermeulen-Oost, R. J. Berkhout, K. C. Wolthers, P. M. Wertheim-van Dillen, J. Kaandorp, J. Spaargaren, and B. Berkhout. 2004. Identification of a new human coronavirus. *Nat. Med.* 10:368–373.
43. Vermeer, P. D., L. A. Einwalter, T. O. Moninger, T. Rokhlina, J. A. Kern, J. Zabner, and M. J. Welsh. 2003. Segregation of receptor and ligand regulates activation of epithelial growth factor receptor. *Nature* 422:322–326.
44. Wang, G., C. Deering, M. Macke, J. Shao, R. Burns, D. M. Blau, K. V. Holmes, B. L. Davidson, S. Perlman, and P. B. McCray, Jr. 2000. Human coronavirus 229E infects polarized airway epithelia from the apical surface. *J. Virol.* 74:9234–9239.
45. Wang, G., V. A. Slepishkin, J. Zabner, S. Keshavjee, J. C. Johnston, S. L. Sauter, D. J. Jolly, T. Dubensky, B. L. Davidson, and P. B. McCray, Jr. 1999. Feline immunodeficiency virus vectors persistently transduce nondividing airway epithelia and correct the cystic fibrosis defect. *J. Clin. Invest.* 104:R49–R56.
46. Woo, P. C., S. K. Lau, C. M. Chu, K. H. Chan, H. W. Tsoi, Y. Huang, B. H. Wong, R. W. Poon, J. J. Cai, W. K. Luk, L. L. Poon, S. S. Wong, Y. Guan, J. S. Peiris, and K. Y. Yuen. 2005. Characterization and complete genome sequence of a novel coronavirus, coronavirus HKU1, from patients with pneumonia. *J. Virol.* 79:884–895.
47. Yang, Z. Y., Y. Huang, L. Ganesh, K. Leung, W. P. Kong, O. Schwartz, K. Subbarao, and G. J. Nabel. 2004. pH-dependent entry of severe acute respiratory syndrome coronavirus is mediated by the spike glycoprotein and enhanced by dendritic cell transfer through DC-SIGN. *J. Virol.* 78:5642–5650.
48. Yeager, C. L., R. A. Ashmun, R. K. Williams, C. B. Cardellicchio, L. H. Shapiro, A. T. Look, and K. V. Holmes. 1992. Human aminopeptidase N is a receptor for human coronavirus 229E. *Nature* 357:420–422.
49. Yu, I. T., Y. Li, T. W. Wong, W. Tam, A. T. Chan, J. H. Lee, D. Y. Leung, and T. Ho. 2004. Evidence of airborne transmission of the severe acute respiratory syndrome virus. *N. Engl. J. Med.* 350:1731–1739.

Angiotensin-converting enzyme 2

W en.wikipedia.org/wiki/Angiotensin-converting_enzyme_2

ACE2




Identifiers


Aliases ACE2, ACEH, angiotensin I converting enzyme 2

External IDs OMIM: 300335 MGI: 1917258 HomoloGene: 41448 GeneCards: ACE2

Gene location (Human)



Chr. X chromosome (human)^[1]



PubMed search

Angiotensin converting enzyme 2 (ACE2)^[5] is an enzyme attached to the outer surface (cell membranes) of cells in the lungs, arteries, heart, kidney, and intestines.^{[6][7]} ACE2 lowers blood pressure by catalysing the cleavage of angiotensin II (a vasoconstrictor peptide) into angiotensin (1-7) (a vasodilator).^{[8][9][10]} ACE2 also serves as the entry point into cells for some coronaviruses.^[5] The human version of the enzyme is often referred to as **hACE2**.^[11]

ACE2 counters the activity of the related angiotensin-converting enzyme (ACE) by reducing the amount of angiotensin-II and increasing Ang(1-7)^[12] making it a promising drug target for treating cardiovascular diseases.^{[13][14]}

Structure

Angiotensin-converting enzyme 2

Identifiers

EC number 3.4.17.23

Databases

IntEnz IntEnz view

BRENDA BRENDA entry

ExPASy NiceZyme view

KEGG KEGG entry

MetaCyc metabolic pathway

PRIAM profile

PDB structures RCSB PDB PDBe PDBsum

Angiotensin-converting enzyme 2 is a zinc containing metalloenzyme located on the surface of endothelial and other cells.^[15] ACE2 protein contains an N-terminal peptidase M2 domain and a C-terminal collectrin renal amino acid transporter domain.^[15]

ACE2 is a single-pass type I membrane protein, with its enzymatically active domain exposed on the surface of cells in lungs and other tissues.^[6] The extracellular domain of ACE2 is cleaved from the transmembrane domain by another enzyme known as

sheddase, and the resulting soluble protein is released into the blood stream and ultimately excreted into urine.^{[16][17]}

Location within the body

ACE2 is known to be present in most organs. ACE2 is attached to the cell membrane of mainly lung alveolar epithelial cells, enterocytes of the small intestine, arterial and venous endothelial cells and arterial smooth muscle cells in most organs. ACE2 mRNA expression is also found in the cerebral cortex, striatum, hypothalamus, and brainstem.^[18]

Function

The primary function of ACE2 is to act as a counter balance to ACE. ACE cleaves angiotensin I hormone into the vasoconstricting angiotensin II. ACE2 in turn cleaves angiotensin II into the vasodilator angiotensin 1–7.^[15] ACE2 can also cleave a number of other peptide including [des-Arg9]-bradykinin, apelin, neurotensin, dynorphin A, and ghrelin.^[15] ACE2 also regulates the membrane trafficking of the neutral amino acid transporter SLC6A19 and has been implicated in Hartnup's disease.^[19]

Coronavirus entry point

As a transmembrane protein, ACE2 serves as the main entry point into cells for some coronaviruses, including HCoV-NL63,^[5] SARS-CoV (the virus that causes SARS),^{[20][21][22]} and SARS-CoV-2^[23] (the virus that causes COVID-19).^{[24][25][26]} More specifically, the binding of the spike S1 protein of SARS-CoV and SARS-CoV2 to the enzymatic domain of ACE2 on the surface of cells results in endocytosis and translocation of both the virus and the enzyme into endosomes located within cells.^{[27][28]} This entry process also requires priming of the S protein by the host serine protease TMPRSS2, the inhibition of which is under current investigation as a potential therapeutic.^[29]

This has led some to hypothesize that decreasing the levels of ACE2, in cells, might help in fighting the infection. On the other hand, ACE2 has been shown to have a protective effect against virus-induced lung injury by increasing the production of the vasodilator angiotensin 1–7.^[30] Furthermore, according to studies conducted on mice, the interaction of the spike protein of the coronavirus with ACE2 induces a drop in the levels of ACE2 in cells through internalization and degradation of the protein and hence may contribute to lung damage.^{[30][31]}

Both ACE inhibitors and angiotensin receptor blockers (ARBs) that are used to treat high blood pressure have been shown in rodent studies to upregulate ACE2 expression hence may affect the severity of coronavirus infections.^{[32][33]} However, multiple professional societies and regulatory bodies have recommended continuing standard ACE inhibitor and ARB therapy.^{[34][35][36]} A systematic review and meta-analysis published on July 11, 2012, found that "use of ACE inhibitors was associated with a significant 34% reduction in

risk of pneumonia compared with controls." Moreover, "the risk of pneumonia was also reduced in patients treated with ACE inhibitors who were at higher risk of pneumonia, in particular those with stroke and heart failure. Use of ACE inhibitors was also associated with a reduction in pneumonia related mortality, although the results were less robust than for overall risk of pneumonia."^[37]

Recombinant human ACE2

Recombinant human ACE2 (rhACE2) is surmised to be a novel therapy for acute lung injury, and appeared to improve pulmonary hemodynamics and oxygen saturation in piglets with a lipopolysaccharide-induced acute respiratory distress syndrome.^[38] The half-life of rhACE2 in human beings is about 10 hours and the onset of action is 30 minutes in addition to the course of effect (duration) of 24 hours.^[38] Several findings suggest that rhACE2 may be a promising drug for those with intolerance to classic renin-angiotensin system inhibitors (RAS inhibitors) or in diseases where circulating angiotensin II is elevated.^[38]

Infused rhACE2 has been evaluated in clinical trials for the treatment of acute respiratory distress syndrome.^[39]

See also

- Renin-angiotensin system
- Angiotensin-converting enzyme
- SARS-Cov-2 § Structural biology

References

1. ^ Jump up to: ^a ^b ^c GRCh38: Ensembl release 89: ENSG00000130234 - Ensembl, May 2017
2. ^ Jump up to: ^a ^b ^c GRCm38: Ensembl release 89: ENSMUSG00000015405 - Ensembl, May 2017
3. ^ "Human PubMed Reference:". *National Center for Biotechnology Information, U.S. National Library of Medicine*.
4. ^ "Mouse PubMed Reference:". *National Center for Biotechnology Information, U.S. National Library of Medicine*.
5. ^ Jump up to: ^a ^b ^c "Gene: ACE2, angiotensin I converting enzyme 2". *National Center for Biotechnology Information (NCBI). U.S. National Library of Medicine*. 2020-02-28.
6. ^ Jump up to: ^a ^b Hamming I, Timens W, Bulthuis ML, Lely AT, Navis G, van Goor H (June 2004). "Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis". *The Journal of Pathology*. **203** (2): 631–7. doi:10.1002/path.1570. PMID 15141377.

7. [△] Donoghue M, Hsieh F, Baronas E, Godbout K, Gosselin M, Stagliano N, Donovan M, Woolf B, Robison K, Jeyaseelan R, Breitbart RE, and Acton S (1 Sep 2000). "A Novel Angiotensin-Converting Enzyme-Related Carboxypeptidase (ACE2) Converts Angiotensin I to Angiotensin 1-9". *Circulation Research*. **87** (5): e1–e9. [doi:10.1161/01.RES.87.5.e1](https://doi.org/10.1161/01.RES.87.5.e1). [PMID 10969042](https://pubmed.ncbi.nlm.nih.gov/10969042/).
8. [△] Keidar S, Kaplan M, Gamliel-Lazarovich A (February 2007). "ACE2 of the heart: From angiotensin I to angiotensin (1-7)". *Cardiovascular Research*. **73** (3): 463–9. [doi:10.1016/j.cardiores.2006.09.006](https://doi.org/10.1016/j.cardiores.2006.09.006). [PMID 17049503](https://pubmed.ncbi.nlm.nih.gov/17049503/).
9. [△] Wang W, McKinnie SM, Farhan M, Paul M, McDonald T, McLean B, et al. (August 2016). "Angiotensin-Converting Enzyme 2 Metabolizes and Partially Inactivates Pyr-Apelin-13 and Apelin-17: Physiological Effects in the Cardiovascular System". *Hypertension*. **68** (2): 365–77. [doi:10.1161/HYPERTENSIONAHA.115.06892](https://doi.org/10.1161/HYPERTENSIONAHA.115.06892). [PMID 27217402](https://pubmed.ncbi.nlm.nih.gov/27217402/).
10. [△] Donoghue M, Hsieh F, Baronas E, Godbout K, Gosselin M, Stagliano N, et al. (September 2000). "A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1–9". *Circulation Research*. **87** (5): E1–9. [doi:10.1161/01.res.87.5.e1](https://doi.org/10.1161/01.res.87.5.e1). [PMID 10969042](https://pubmed.ncbi.nlm.nih.gov/10969042/).
11. [△] Kasmi Y, Khataby K, Souiri A (2019). "*Coronaviridae: 100,000 Years of Emergence and Reemergence*". In Ennaji MM (ed.). *Emerging and Reemerging Viral Pathogens. Volume 1: Fundamental and Basic Virology Aspects of Human, Animal and Plant Pathogens*. Elsevier. p. 135. [ISBN 978-0-12-819400-3](https://doi.org/10.1016/B978-0-12-819400-3).
12. [△] Chamsi-Pasha MA, Shao Z, Tang WH (March 2014). "*Angiotensin-converting enzyme 2 as a therapeutic target for heart failure*". *Current Heart Failure Reports*. Springer Science and Business Media LLC. **11** (1): 58–63. [doi:10.1007/s11897-013-0178-0](https://doi.org/10.1007/s11897-013-0178-0). [PMC 3944399](https://pubmed.ncbi.nlm.nih.gov/24293035/). [PMID 24293035](https://pubmed.ncbi.nlm.nih.gov/24293035/). "The discovery of ACE2 and its role in counteracting the effect of Ang-II through Ang(1-7) formation...An imbalance in ACE2/Ang-(1-7) and ACE/Ang-II axes is critical in the development of cardiovascular diseases. The central role of ACE2, therefore, appears to counter ACE activity by reducing Ang-II bioavailability and increasing Ang(1-7) formation...The use of RAS-modulating agents and molecules as novel therapeutic agents in hypertension and cardiovascular therapeutic research."
13. [△] Chamsi-Pasha MA, Shao Z, Tang WH (March 2014). "*Angiotensin-converting enzyme 2 as a therapeutic target for heart failure*". *Current Heart Failure Reports*. Springer Science and Business Media LLC. **11** (1): 58–63. [doi:10.1007/s11897-013-0178-0](https://doi.org/10.1007/s11897-013-0178-0). [PMC 3944399](https://pubmed.ncbi.nlm.nih.gov/24293035/). [PMID 24293035](https://pubmed.ncbi.nlm.nih.gov/24293035/). "Studies with recombinant human ACE2 (rhACE2) have shown beneficial cardiac effects [18, 36]. rhACE2 has anti-fibrotic properties and can attenuate effect on systolic and diastolic dysfunction, presumably via Ang-II inhibition."
14. [△] ^{Jump up to:} ^{[a](#)} ^{[b](#)} ^{[c](#)} ^{[d](#)} Turner AJ (2015). "Chapter 25: ACE2 Cell Biology, Regulation, and Physiological Functions". In Unger T, Ulrike M, Steckelings UM, dos Santos RA (eds.). *The Protective Arm of the Renin Angiotensin System (RAS): Functional Aspects and Therapeutic Implications*. Academic Press. pp. 185–189. [doi:10.1016/B978-0-12-801364-9.00025-0](https://doi.org/10.1016/B978-0-12-801364-9.00025-0). [ISBN 978-0-12-801364-9](https://doi.org/10.1016/B978-0-12-801364-9).

15. ^ Lambert DW, Yarski M, Warner FJ, Thornhill P, Parkin ET, Smith AI, et al. (August 2005). "Tumor necrosis factor-alpha convertase (ADAM17) mediates regulated ectodomain shedding of the severe-acute respiratory syndrome-coronavirus (SARS-CoV) receptor, angiotensin-converting enzyme-2 (ACE2)". *The Journal of Biological Chemistry*. **280** (34): 30113–9. doi:10.1074/jbc.M505111200. PMID 15983030.
16. ^ Patel VB, Clarke N, Wang Z, Fan D, Parajuli N, Basu R, et al. (January 2014). "Angiotensin II induced proteolytic cleavage of myocardial ACE2 is mediated by TACE/ADAM-17: a positive feedback mechanism in the RAS". *Journal of Molecular and Cellular Cardiology*. **66**: 167–76. doi:10.1016/j.yjmcc.2013.11.017. PMID 24332999.
17. ^ Fehr AR, Perlman S (2015). "Coronaviruses: an overview of their replication and pathogenesis". *Methods in Molecular Biology*. Springer New York. **1282**: 1–23. doi:10.1007/978-1-4939-2438-7_1. ISBN 978-1-4939-2437-0. PMC 4369385. PMID 25720466. "Many α-coronaviruses utilize aminopeptidase N (APN) as their receptor, SARS-CoV and HCoV-NL63 use angiotensin-converting enzyme 2 (ACE2) as their receptor, MHV enters through CEACAM1, and the recently identified MERS-CoV binds to dipeptidyl-peptidase 4 (DPP4) to gain entry into human cells (See Table 1 for a list of known CoV receptors)."
18. ^ Li F (October 2013). "Receptor recognition and cross-species infections of SARS coronavirus". *Antiviral Research*. **100** (1): 246–54. doi:10.1016/j.antiviral.2013.08.014. PMC 3840050. PMID 23994189.
19. ^ Kuba K, Imai Y, Rao S, Gao H, Guo F, Guan B, et al. (August 2005). "A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury". *Nature Medicine*. **11** (8): 875–9. doi:10.1038/nm1267. PMC 7095783. PMID 16007097.
20. ^ "What are the official names of the disease and the virus that causes it?". Q&A on coronaviruses. World Health Organization. Archived from the original on 5 March 2020. Retrieved 22 February 2020.
21. ^ Zhou P, Yang XL, Wang XG, Hu B, Zhang L, Zhang W, et al. (March 2020). "A pneumonia outbreak associated with a new coronavirus of probable bat origin". *Nature*. **579** (7798): 270–273. doi:10.1038/s41586-020-2012-7. PMC 7095418. PMID 32015507.
22. ^ Xu X, Chen P, Wang J, Feng J, Zhou H, Li X, et al. (March 2020). "Evolution of the novel coronavirus from the ongoing Wuhan outbreak and modeling of its spike protein for risk of human transmission". *Science China. Life Sciences*. **63** (3): 457–460. doi:10.1007/s11427-020-1637-5. PMC 7089049. PMID 32009228.
23. ^ Lewis R (2020-02-20). "COVID-19 Vaccine Will Close in on the Spikes". *DNA Science Blog*. Public Library of Science. Archived from the original on 2020-02-22. Retrieved 2020-02-22.
24. ^ Wang H, Yang P, Liu K, Guo F, Zhang Y, Zhang G, Jiang C (February 2008). "SARS coronavirus entry into host cells through a novel clathrin- and caveolae-independent endocytic pathway". *Cell Research*. **18** (2): 290–301. doi:10.1038/cr.2008.15. PMC 7091891. PMID 18227861.
25. ^ Millet JK, Whittaker GR (April 2018). "Physiological and molecular triggers for SARS-CoV membrane fusion and entry into host cells". *Virology*. **517**: 3–8. doi:10.1016/j.virol.2017.12.015. PMC 7112017. PMID 29275820.

26. [^] Akhmerov Akbarshakh; Marban Eduardo. *"COVID-19 and the Heart"*. *Circulation Research*. **0** (0). doi:10.1161/CIRCRESAHA.120.317055.
27. [^] Jia H (September 2016). *"Pulmonary Angiotensin-Converting Enzyme 2 (ACE2) and Inflammatory Lung Disease"*. *Shock*. Augusta, Ga. **46** (3): 239–48. doi:10.1097/SHK.0000000000000633. PMID 27082314. *"Once SARS-CoV binds to its receptor, the abundance on the cell surface, mRNA expression and the enzymatic activity of ACE2 are significantly reduced. ... These effects are, in part, due to enhanced shedding/internalizing processes. ... The spike protein binds to ACE2 and subsequently down regulated ACE2 protein expression and resulted in worsened acid aspiration pneumonia"*
28. [^] Nicholls J, Peiris M (August 2005). *"Good ACE, bad ACE do battle in lung injury, SARS"*. *Nature Medicine*. **11** (8): 821–2. doi:10.1038/nm0805-821. PMC 7095949. PMID 16079870.
29. [^] *"Position Statement of the ESC Council on Hypertension on ACE-Inhibitors and Angiotensin Receptor Blockers"*. European Society of Cardiology (ESC). 13 March 2020. *Lay summary* – Medscape.
30. [^] *"EMA advises continued use of medicines for hypertension, heart or kidney disease during COVID-19 pandemic"*. European Medicines Agency (EMA). 27 March 2020. *Lay summary* – Medscape.
31. [^] *"HFSA/ACC/AHA Statement Addresses Concerns Re: Using RAAS Antagonists in COVID-19"*. American College of Cardiology (ACC). 27 March 2020. *Lay summary* – Medscape.
32. [^] Caldeira D, Alarcão J, Vaz-Carneiro A, Costa J (July 2012). *"Risk of pneumonia associated with use of angiotensin converting enzyme inhibitors and angiotensin receptor blockers: systematic review and meta-analysis"*. *BMJ*. **345** (jul11 1): e4260. doi:10.1136/bmj.e4260. PMC 3394697. PMID 22786934. *"Our results suggest an important role of ACE inhibitors, but not ARBs, in reducing the risk of pneumonia. These data may discourage the withdrawal of ACE inhibitors in some patients with tolerable adverse events (namely, cough) who are at particularly high risk of pneumonia. ACE inhibitors also lowered the risk of pneumonia related mortality, mainly in patients with established disease, but the robustness of the evidence was weaker."*
33. [^] *Jump up to:* ^a ^b ^c Colafella KM, Uijl E, Danser J (2019). *"Interference With the Renin–Angiotensin System (RAS): Classical Inhibitors and Novel Approaches"*. *Encyclopedia of Endocrine Diseases*. Elsevier. pp. 523–530. doi:10.1016/b978-0-12-801238-3.65341-2. ISBN 978-0-12-812200-6.
34. [^] Khan A, Benthin C, Zeno B, Albertson TE, Boyd J, Christie JD, et al. (September 2017). *"A pilot clinical trial of recombinant human angiotensin-converting enzyme 2 in acute respiratory distress syndrome"*. *Critical Care*. **21** (1): 234. doi:10.1186/s13054-017-1823-x. PMC 5588692. PMID 28877748.

External links

Human *ACE2* genome location and *ACE2* gene details page in the [UCSC Genome Browser](#).